Pancreatic Cancer Research

ResearcherFred and Pamela Buffett Cancer CenterActive in the last 2 years

Kavita B. Mallya

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6562-5827; OpenAlex author ID A5005591732; NIH RePORTER profile ID 16172563. Sources: OpenAlex.

Their work

Papers
24 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
1
Collaborators
79
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 3 papers · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 6 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers, 1 grant

Papers 24

  1. Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218276↗
  2. Distinct glycosyltransferase expression governs organ-specific survival in pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-026-03896-5↗
  3. Mucin4 (MUC4) Antibody Labeled with an NIR Dye Brightly Targets Pancreatic Cancer Liver Metastases and Peritoneal Carcinomatosis. Co-author DOI 10.3390/cancers17122031↗
  4. Brightly Visualizing Pancreatic Cancer Margins in Orthotopic Mouse Models with an Anti-CA19-9 Antibody Conjugated to a Near-Infrared Fluorophore. Co-author DOI 10.3390/cancers17162617↗
  5. Targeting Human Pancreatic Cancer with a Fluorophore-Conjugated Mucin 4 (MUC4) Antibody: Initial Characterization in Orthotopic Cell Line Mouse Models. Co-author DOI 10.3390/jcm13206211↗
  6. Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study. Co-author DOI 10.3390/jpm13050857↗
  7. Reduction in O-glycome induces differentially glycosylated CD44 to promote stemness and metastasis in pancreatic cancer. Co-author DOI 10.1038/s41388-021-02047-2↗
  8. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-022-02493-6↗
  9. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance. Co-author DOI 10.1053/j.gastro.2021.09.017↗
  10. MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. Co-author DOI 10.1158/1541-7786.mcr-21-0888↗
  11. Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft. Co-author DOI 10.21873/invivo.12676↗
  12. Ubiquitous Aberration in Cholesterol Metabolism across Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/metabo12010047↗
  13. Modeling pancreatic cancer in mice for experimental therapeutics. Co-author DOI 10.1016/j.bbcan.2021.188554↗
  14. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-020-01518-2↗
  15. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-020-01564-w↗
  16. Acinar transformed ductal cells exhibit differential mucin expression in a tamoxifen-induced pancreatic ductal adenocarcinoma mouse model. Co-author DOI 10.1242/bio.052878↗
  17. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. Co-author DOI 10.1038/ajg.2016.482↗
  18. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Co-author DOI 10.1038/ncb3169↗
  19. MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-κB signaling in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-2174↗
  20. Quantitative real-time PCR expression analysis of peripheral blood mononuclear cells in pancreatic cancer patients. First author DOI 10.1007/978-1-62703-287-2_8↗
  21. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. Co-author DOI 10.1371/journal.pone.0055171↗
  22. Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and the… Co-author DOI 10.1371/journal.pone.0080580↗
  23. Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. Co-author DOI 10.1371/journal.pone.0017014↗
  24. Differential gene expression analysis of peripheral blood mononuclear cells reveals novel test for early detection of pancreatic cancer. Co-author DOI 10.3233/cbm-2012-0260↗

Grants 1

  1. Novel Models and Biorepository For Early Detection And Therapeutic Intervention Of Pancreatic Cancer R50CA305093↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Surinder K. Batra · 24 shared papers, 2011–2026 · strength 2.86
  2. Maneesh Jain · 10 shared papers, 2013–2025 · strength 1.26
  3. Moorthy Palanimuthu Ponnusamy · 7 shared papers, 2021–2026 · strength 1.06
  4. Sanchita Rauth · 7 shared papers, 2021–2026 · strength 1.05
  5. Michael Bouvet · 5 shared papers, 2022–2025 · strength 0.93
  6. Robert M. Hoffman · 5 shared papers, 2022–2025 · strength 0.93
  7. Palanisamy Nallasamy · 5 shared papers, 2021–2026 · strength 0.83
  8. Saravanakumar Marimuthu · 5 shared papers, 2021–2026 · strength 0.82
  9. Satyanarayana Rachagani · 9 shared papers, 2011–2022 · strength 0.82
  10. Aaron M. Mohs · 4 shared papers, 2023–2025 · strength 0.78
  11. Parthasarathy Seshacharyulu · 5 shared papers, 2020–2026 · strength 0.73
  12. Paul M. Grandgenett · 5 shared papers, 2015–2026 · strength 0.62
  13. Sunidhi Jaiswal · 3 shared papers, 2024–2025 · strength 0.62
  14. Rama Krishna Nimmakayala · 5 shared papers, 2021–2022 · strength 0.58
  15. Michael Anthony Hollingsworth · 6 shared papers, 2014–2026 · strength 0.57
  16. Kristin E. Cox · 3 shared papers, 2023–2025 · strength 0.55
  17. Thinzar Min Lwin · 3 shared papers, 2022–2025 · strength 0.53
  18. Subodh M. Lele · 4 shared papers, 2014–2026 · strength 0.50
  19. Ashu Shah · 3 shared papers, 2022–2026 · strength 0.50
  20. Jesse L. Cox · 3 shared papers, 2022–2026 · strength 0.49
  21. Venkatesh Varadharaj · 2 shared papers, 2026 · strength 0.48
  22. Zahraa Wajih Alsafwani · 2 shared papers, 2026 · strength 0.48
  23. Frank Leon · 3 shared papers, 2021–2026 · strength 0.46
  24. Sukhwinder Kaur · 6 shared papers, 2011–2022 · strength 0.42
  25. Shailendra Kumar Gautam · 3 shared papers, 2021–2022 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.